Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion

Regeneron Pharmaceuticals, Inc. (REGN) announced that the blockbuster asthma drug Dupixent (dupilumab) has been recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP") for approval for an additional indication. The CHMP recommended the label expansion of Dupixent in the European Union (EU) for eosinophilic esophagitis (EoE) in children down to 1 year of age. The recommendation is for children aged 1 to 11 years who weigh at least 15 kg and are inadequately cont ...